Association of Drug-Metabolizing Enzyme and Transporter Gene Polymorphisms and Lipid-Lowering Response to Statins in Thai Patients with Dyslipidemia
1
Issued Date
2022-01-01
Resource Type
eISSN
11787066
Scopus ID
2-s2.0-85125044630
Journal Title
Pharmacogenomics and Personalized Medicine
Volume
15
Start Page
119
End Page
130
Rights Holder(s)
SCOPUS
Bibliographic Citation
Pharmacogenomics and Personalized Medicine Vol.15 (2022) , 119-130
Suggested Citation
Vanwong N., Tipnoppanon S., Na Nakorn C., Srisawasdi P., Rodcharoen P., Medhasi S., Chariyavilaskul P., Siwamogsatham S., Vorasettakarnkij Y., Sukasem C. Association of Drug-Metabolizing Enzyme and Transporter Gene Polymorphisms and Lipid-Lowering Response to Statins in Thai Patients with Dyslipidemia. Pharmacogenomics and Personalized Medicine Vol.15 (2022) , 119-130. 130. doi:10.2147/PGPM.S346093 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/83925
Title
Association of Drug-Metabolizing Enzyme and Transporter Gene Polymorphisms and Lipid-Lowering Response to Statins in Thai Patients with Dyslipidemia
Other Contributor(s)
Abstract
Purpose: Statins are increasingly widely used in the primary and secondary prevention of cardiovascular disease. However, there is an inter-individual variation in statin response among patients. The study aims to determine the association between genetic variations in drug-metabolizing enzyme and transporter (DMET) genes and lipid-lowering response to a statin in Thai patients with hyperlipidemia. Patients and Methods: Seventy-nine patients who received statin at steady-state concentrations were recruited. Serum lipid profile was measured at baseline and repeated after 4-month on a statin regimen. The genotype profile of 1936 DMET markers was obtained using Affymetrix DMET Plus genotyping microarrays. Results: In this DMET microarray platform, five variants; SLCO1B3 (rs4149117, rs7311358, and rs2053098), QPRT (rs13331798), and SLC10A2 (rs188096) showed a suggestive association with LDL-cholesterol-lowering response. HDL-cholesterol-lowering responses were found to be related to CYP7A1 gene variant (rs12542233). Seven variants, SLCO1B3 (rs4149117, rs7311358, and rs2053098); SULT1E1 (rs3736599 and rs3822172); and ABCB11 (rs4148768 and rs3770603), were associated with the total cholesterol-lowering response. One variant of the ABCB4 gene (rs2109505) was significantly associated with triglyceride-lowering response. Conclusion: This pharmacogenomic study identifies new genetic variants of DMET genes that are associated with the lipid-lowering response to statins. Genetic polymorphisms in DMET genes may impact the pharmacokinetics and lipid-lowering response to statin. The validation studies confirmations are needed in future pharmacogenomic studies.